Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Kristen Nowak to Disease Progression

This is a "connection" page, showing publications Kristen Nowak has written about Disease Progression.

 
Connection Strength
 
 
 
1.103
 
  1. Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial. Am J Kidney Dis. 2024 09; 84(3):275-285.e1.
    View in: PubMed
    Score: 0.477
  2. Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021 06; 16(6):908-915.
    View in: PubMed
    Score: 0.098
  3. Nowak KL, Chonchol M, Jovanovich A, You Z, Ambrosius WT, Cho ME, Glasser S, Lash J, Simmons DL, Taylor A, Weiner D, Rastogi A, Oparil S, Supiano MA. Arterial stiffness and kidney disease progression in the systolic blood pressure intervention trial?. Clin Nephrol. 2020 Jul; 94(1):26-35.
    View in: PubMed
    Score: 0.092
  4. Nowak KL, Hopp K. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clin J Am Soc Nephrol. 2020 04 07; 15(4):577-584.
    View in: PubMed
    Score: 0.090
  5. Nowak KL, Chonchol M, You Z, Gupta M, Gitomer B. Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study?. Clin Nephrol. 2018 Mar; 89(3):196-204.
    View in: PubMed
    Score: 0.078
  6. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578.
    View in: PubMed
    Score: 0.076
  7. Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2016; 44(3):171-8.
    View in: PubMed
    Score: 0.070
  8. Dahl NK, August P, Besse W, Chebib FT, Chonchol M, Cowley BD, Goral S, Guay-Woodford LM, Gulati A, Hogan MC, Lakhia R, Miskulin D, Nowak KL, Rahbari-Oskoui F, Park M, Seliger S, Yu A, Watnick T. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Am J Kidney Dis. 2026 Apr; 87(4):447-507.
    View in: PubMed
    Score: 0.034
  9. Gitomer BY, Ostrow A, Wang W, George D, Coleman E, Nowak KL, Cadnapaphornchai MA, Patel NU, Steele C, Jovanovich A, Klawitter J, Farmer B, You Z, Chonchol M. A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease. Kidney Int. 2026 Feb; 109(2):390-397.
    View in: PubMed
    Score: 0.033
  10. Gitomer BY, Wang W, George D, Coleman E, Nowak KL, Struemph T, Cadnapaphornchai MA, Patel NU, Jovanovich A, Klawitter J, Farmer B, Ostrow A, You Z, Chonchol M. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics. Contemp Clin Trials. 2024 02; 137:107423.
    View in: PubMed
    Score: 0.029
  11. Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 04; 79(4):518-526.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)